Key Highlights

  • Spirax Group is one of the London market's quintessential quality-industrial names, the sort of Business that compounds quietly through cycles by embedding itself in customers' critical processes.
  • Yet the past couple of years have tested that reputation, as sluggish global industrial production and a de-rating from lofty multiples humbled a former stock-market darling.
  • Revenue rose 5% both reported and organically to £863.8m, comfortably ahead of global industrial production growth of around 1.5%.
  • Adjusted operating profit increased 8% to £171.1m, lifting the adjusted Operating Margin 50 basis points to 19.8%, while adjusted Earnings Per Share grew 9% to 150.0p.

Spirax Group is one of the London market's quintessential quality-industrial names, the sort of business that compounds quietly through cycles by embedding itself in customers' critical processes. Yet the past couple of years have tested that reputation, as sluggish global industrial production and a de-rating from lofty multiples humbled a former stock-market darling. The half-year results to mid-2026 offered reassurance that the Franchise is still outgrowing its end markets, but they also underlined that the recovery remains a work in progress — a genuine test of the group's resilience and its claim to premium quality.

First half in line

The interim numbers were solid if unspectacular. Revenue rose 5% both reported and organically to £863.8m, comfortably ahead of global industrial production growth of around 1.5%. Adjusted operating profit increased 8% to £171.1m, lifting the adjusted operating margin 50 basis points to 19.8%, while adjusted earnings per share grew 9% to 150.0p. The Dividend was raised 3% to 50.4p. Management reiterated full-year guidance of mid-single-digit organic revenue growth with further margin progression, signalling confidence that the improvement seen in the first half can be sustained. The result kept intact a long record of revenue growth outpacing the industrial economy, the feature that historically justified the group's premium rating.

Three engines, uneven progress

Spirax runs three divisions, and their trajectories diverged. Steam Thermal Solutions, the historic core supplying steam-system products and services, grew just 1% organically, though Demand outpaced industrial production by more than two to one. Electric Thermal Solutions was the star, up 11% organically with strong cross-divisional pull-through. Watson-Marlow Fluid Technology Solutions, the peristaltic-pump business geared to biopharma, rose 7% organically, with biopharm orders running ahead of sales — an encouraging leading indicator after a prolonged destocking cycle in that sector weighed on the group. The mix matters, because Watson-Marlow and the aftermarket carry some of the highest margins in the portfolio, so recovery there lifts group profitability disproportionately.

The self-help and cash angle

Spirax's appeal rests on a high proportion of recurring, aftermarket and consumable revenue, giving it pricing power and defensive characteristics that many industrials lack. Return on Capital employed improved 180 basis points year on year. The one clear disappointment was cash: adjusted cash conversion fell around 700 basis points to 54%, which management attributed to seasonality and inventory build. Weaker cash generation prompted a notable share-price reaction on results day, a reminder that investors are scrutinising conversion as closely as headline growth after a period of underperformance. Management framed the shortfall as timing rather than structural, but a second consecutive weak conversion print would raise sharper questions about working-capital discipline.

Risks and the macro backdrop

The central risk is the industrial cycle itself. Spirax's premium rating assumes a return to broad-based growth, and a stalled or slipping recovery in global Manufacturing would pressure both volumes and sentiment. Biopharma demand, while improving, has proved volatile. Currency translation matters for a group with global reach, and the soft cash conversion needs to reverse to reassure the market. Competition, input-cost Inflation and the pace at which electrification and decarbonisation drive new demand for its thermal solutions all add layers of uncertainty to the outlook. Any renewed customer destocking, particularly in biopharma, could quickly interrupt the nascent order recovery.

Outlook

Spirax remains a high-quality franchise that is once again growing ahead of its end markets, but the shares are effectively being asked to prove the recovery is real. The key question is whether industrial production firms enough to lift the lagging Steam business while Electric Thermal and Watson-Marlow maintain momentum. Investors may watch second-half cash conversion, biopharm order trends, margin delivery against guidance, and any inflection in global manufacturing indicators. Consistent execution could restore confidence in the compounding story; continued cash softness or a weaker macro backdrop would keep the recovery test unresolved.